Business
10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products
10x Genomics is seeking additional injunctions to protect its intellectual property PLEASANTON, Calif., May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc.
About this update from 10x Genomics, Inc.
[{"type":"text","content":"10x Genomics is seeking additional injunctions to protect its intellectual property\nPLEASANTON, Calif., May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and NanoString Technologies Germany GmbH.\n\n \n \n \n \n \n \n\n \nThe Munich Regional Court issued a permanent injunction today that - once provisionally enforced against a security bond - requires NanoString to stop selling and supplying the CosMx Spatial Molecular Imager (CosMx SMI) instruments as well as CosMx reagents for RNA detection in Germany. The Munich Regional Court issued the injunction based on its finding that the CosMx products infringe European Patent Number 2794928B1, which relates to in situ detection of analytes. In its decision, the Munich Regional Court referenced an earlier preliminary opinion by the German Federal Patent Court finding the asserted claims of the patent valid.\n\"10x has invested more than $1 billion in cutting edge research and development, resulting in many breakthrough products and more than 800 patents, including foundational intellectual property for our in situ products,\" said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. \"If we are to continue to be on the forefront of innovation, we cannot stand by and simply allow others to take and use our intellectual property. We have already requested an injunction against NanoString's infringing CosMx products in the United States and expect to seek other injunctions where NanoString's infringing CosMx products are sold.\"\n10x Genomics filed its patent infringement lawsuit against NanoString in Germany in March 2022. Despite the risk of an injunction and the significant repercussions it could have on researchers, NanoString has continued to market CosMx to labs worldwide. Nicole Droste, NanoString's Vice President of Sales, EMEA, understood this, declaring under oath, \"An injunction against NanoString in Germany would likely make customers in other European countries fearful of purchasing a CosMx instrument because they may not be able to use it for RNA detection.\" Ms. Droste also recognized the international consequences of infringing patents, \"An injunction issued by the German Court could likel...